AstraZeneca Forxiga meets primary endpoint for type 2 diabetes Ruchika Sharma8 Oct 2023 10:00 AM ISTCambridge: AstraZeneca has announced positive results from the T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed...
Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper Dr. Nandita Mohan30 Sept 2023 11:30 AM IST As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin...
USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients MD Brand Connect4 Sept 2023 1:55 PM ISTUSV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment...
SGLT2 inhibitors failed to improve survival in patients hospitalised with COVID-19 Dr. Kamal Kant Kohli31 Aug 2023 10:00 AM ISTUSA: Findings from a recent study failed to support the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients hospitalized with...
ESC 2023 Update: Dapagliflozin fails to improve diuretic efficiency in acute heart failure: DICTATE-AHF trial Dr. Kamal Kant Kohli31 Aug 2023 8:30 AM ISTUSA: Dapagliflozin can be safely started upon hospital admission to rapidly optimise guideline-directed medical therapy (GDMT) among hospitalized...
Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Antidiabetic FDC Drug Dr. Divya Colin30 Aug 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, Sun Pharma Laboratories has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
AstraZeneca Forxiga approved in China to reduce cardiovascular death, hospitalisation risk in adults with symptomatic chronic heart failure Ruchika Sharma20 Aug 2023 1:30 PM ISTForxiga is a first-in-class, oral, once-daily selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2).
Dapagliflozin suitable adjunct therapy to improve body composition in patients with type 2 diabetes Medha Baranwal17 Aug 2023 11:30 AM ISTSouth Korea: A recent study compared the therapeutic safety and efficacy of dapagliflozin, sitagliptin, or lobeglitazone adjunct therapy in type 2...
USV Launches Jalra Trio for Management of Type 2 Diabetes in India MD Brand Connect11 Aug 2023 12:22 PM ISTUSV Pvt. Ltd, a leading drug manufacturer in the anti-diabetic segment, has announced the launch of the brand Jalra Trio for the treatment of...
New products, nutraceuticals added under Jan Aushadhi Pariyojana Ruchika Sharma30 July 2023 10:00 AM ISTThe product basket of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has 1800 medicines, 285 Surgical Equipment and Consumables.
Dapagliflozin use linked to sarcopenia in non obese patients of type 1 diabetes Dr. Kamal Kant Kohli29 July 2023 11:30 AM ISTDapagliflozin treatment of individuals with type 1 diabetes, particularly non-obese individuals and older men, might result in loss of skeletal muscle...
Dapagliflozin not better than metolazone at relieving congestion in HF patients with loop diuretic resistance Dr. Kamal Kant Kohli19 July 2023 9:15 AM ISTA recent study published in European Heart Journal showed a randomized trial comparing the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
